Sophie Boutaud de la Combe, Director of Office of Public Information and Communication at the International Atomic Energy Agency (IAEA), visited Shenzhen CNNC Headway Bio-Sci & Tech Co., Ltd. on August 29, 2024, in Shenzhen, South China’s Guangdong Province, a pioneer of China’s reform and opening-up.

The IAEA official learned about China’s medical applications of nuclear technology during her visit. Shenzhen CNNC Headway Bio-Sci & Tech Co., Ltd. has focused on innovations in isotopes and the pharmaceutical industry for many years.

The company is engaged in the research, development, production, and sales of diagnostic urea breath test drugs and related detection instruments for Helicobacter pylori infections. Headway products cover 32 provinces in domestic market and are provided to 82 countries and regions worldwide.

Sophie highly recognized the achievements made by China Tongfu and China Nuclear Headway in the field of nuclear technology application, and hoped that the IAEA could continue to expand cooperation with China company in scientific research and other fields in the future, and jointly make greater contributions to protecting human health.

The participants visited the exhibition hall and production workshop of CNNC Headway together, watched the popular science video “The Harm of Helicobacter pylori”, experienced the Helicobacter pylori breath test, and understood the development process and industry situation of the breath diagnosis industry in detail.

Helicobacter pylori is a primary carcinogen of stomach cancer and one of the most commonly infected bacteria worldwide. In China, the overall infection rate of H. pylori in residents is nearly 50%, which has the characteristics of high population infection rate, heavy disease burden and high drug resistance rate.

Helicobacter pylori infection is difficult to heal itself, if not treated often a lifelong infection. Helicobacter pylori infection control is the most important and controllable means to prevent gastric cancer.

Early screening and eradication of Helicobacter pylori can effectively reduce the incidence of gastric cancer. Urea [13C]/[14C] breath test for Helicobacter pylori detection has the characteristics of non-invasive, rapid, simple operation, high sensitivity and specificity, and is the most widely used method for Helicobacter pylori detection in China.

Adhering to the “people first, life first”,  Headway has been deeply engaged in the field of breath diagnosis for 28 years, focusing on the application and innovation of breath detection technology, and implementing the corporate purpose of “making human health easier” with practical actions. Contribute to the development of World wide medical and health cause “China Nuclear Headway power”!